VIVEbiotech participa en el proyecto europeo MAGIC
El consorcio MAGIC pretende
tener un impacto significativo en la vida de personas afectadas por distrofias musculares.
Noticias relacionadas con terapia génica y celular.
VIVEbiotech participa en el proyecto europeo MAGIC
CRISPR-Cas:From biology to therapeutic
Global Awards for Research in DMD-AWARD
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network
WADA invites applications for research projects on the development of gene doping detection methods
Nuestras cifras y logros del 2022
FDA approval of the world’s first gene therapy for Haemophilia
SETGYC 2022 Oral and Poster Award Winners
Outreach opportunity as a translator for EuroGCT
In memory of Dr. Manfred Schmidt